{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:25:38Z","timestamp":1757701538869},"reference-count":12,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":3497,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[1998,12]]},"abstract":"<jats:p><jats:bold>Summary.<\/jats:bold>A multicentre, randomized, doubleblind, parallel\u2010group trial was conducted to compare the efficacy and safety of two dosages of itraconazole in the treatment of tinea pedis or manuum. Of the 135 patients recruited, 66 received itraconazole 400 mg daily for 1 week and 69 received itraconazole 100 mg daily for 4 weeks. In the evaluable patients observed\u2010case analysis, mycological cure was seen in 63% of patients in the 400 mg\/1 week group and in 75% in the 100 mg\/4 weeks group at the end of a 6\u2010week follow\u2010up period (not significantly equivalent). In the evaluable patients worst\u2010case analysis and the intention\u2010to\u2010treat analysis, mycological cure rates in the two groups were borderline significantly equivalent at the end of follow\u2010up (range 51\u201357%). Clinical response was seen in 81% of evaluable patients in the 400 mg\/1 week group and in 75% in the 100 mg\/4 weeks group at the end of follow\u2010up; equivalence testing showed the 400 mg\/1 week regimen to be at least equivalent to the 100 mg\/4 week regimen. Similar results were found in the intention\u2010to\u2010treat analysis, and tolerability ratings for the two treatment regimens were significantly equivalent. This trial has shown that itraconazole 400 mg\/1 week and itraconazole 100 mg\/4 weeks are both effective regimens for the treatment of tinea pedis or manuum. The two treatment schedules were equally well tolerated and safe.<\/jats:p><jats:p><jats:bold>Zusammenfassung.<\/jats:bold>Zum Vergleich der Wirksamkeit und Sicherheit von zwei Itraconazol\u2010Dosierungen bei der Behandlung der Tinea pedis oder manuum wurde eine randomisierte, doppelblinde Multicentre\u2010Parallelgruppenstudie durchgef\u00fchrt. Von den 135 Patienten wurden 66 Patienten 1 Woche lang mit 400 mg Itraconazol t\u00e4glich und 69 Patienten 4 Wochen lang mit 100 mg Itraconazol t\u00e4glich behandelt. Bei der Observed\u2010case\u2010Analyse der evaluierbaren Patienten wurde bei der Nachuntersuchung nach 6 Wochen bei 63% der Patienten der Gruppe mit 400 mg\/1 Woche und 75% der Patienten der Gruppe mit 100 mg\/4 Wochen eine mykologische Heilung festgestellt (nicht signifikant \u00e4quivalent). In der Worst\u2010case\u2010Analyse der evaluierbaren Patienten und der Intention\u2010to\u2010treat\u2010Analyse waren die mykologischen Heilungsergebnisse bei der Nachuntersuchung grenzwertig signifikant \u00e4quivalent (51\u201357%). Bei der Nachuntersuchung wurde bei 81% der evaluierbaren Patienten der Gruppe mit 400 mg\/1 Woche und bei 75% der Gruppe mit 100 mg\/4 Wochen ein klinischer Respons beobachtet. \u00c4quivalenztests ergaben, da\u00df die Behandlungspl\u00e4ne mindestens \u00e4quivalent waren. Die Intention\u2010to\u2010treat\u2010Analyse f\u00fchrte zu \u00e4hnlichen Ergebnissen, und die Vertr\u00e4glichkeitsbewertung war bei beiden Therapien signifikant \u00e4quivalent. Diese Studie ergab, da\u00df Itraconazol 400 mg\/1 Woche und Itraconazol 100 mg\/4 Wochen wirksame Therapien f\u00fcr die Tinea pedis oder manuum sind. Beide Behandlungsschemata sind gleich gut vertr\u00e4glich und sicher.<\/jats:p>","DOI":"10.1111\/j.1439-0507.1998.tb00715.x","type":"journal-article","created":{"date-parts":[[2010,7,24]],"date-time":"2010-07-24T23:35:07Z","timestamp":1280014507000},"page":"515-520","source":"Crossref","is-referenced-by-count":16,"title":["Itraconazole in the treatment of tinea pedis and tinea manuum: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea pedis und Tinea manuum: Vergleich zweier Behandlungsschemata"],"prefix":"10.1111","volume":"41","author":[{"given":"J.","family":"Schuller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Remme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. H. J.","family":"Rampen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. C. J.","family":"Van Neer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"2421","volume-title":"Dermatology in General Medicine","author":"Martin A. G.","year":"1993"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)91838-8"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6295.825"},{"issue":"2","key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1439-0507.1989.tb02312.x","article-title":"Safety aspects of ketoconazole, the most commonly used systemic antifungal.","volume":"32","author":"Cauwenbergh G.","year":"1989","journal-title":"Mycoses"},{"key":"e_1_2_1_6_2","first-page":"118","article-title":"Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review","volume":"44","author":"Doncker P.","year":"1990","journal-title":"Br. J. Clin. Pract."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/9.Supplement_1.S15"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1989.tb02290.x"},{"key":"e_1_2_1_9_2","first-page":"814","article-title":"Safety aspects of itraconazole therapy in vaginal candidosis, dermatomycosis and onychomycosis: a review","volume":"49","author":"Beule K.","year":"1991","journal-title":"Curr. Ther. Res."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70037-7"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90064-0"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1995.tb03596.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80351-9"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.1998.tb00715.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.1998.tb00715.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T18:19:01Z","timestamp":1711649941000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.1998.tb00715.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":12,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["10.1111\/j.1439-0507.1998.tb00715.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.1998.tb00715.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}